Cost of care distribution in atrial fibrillation patients: the COCAF study

Heuzey, Jean‐Yves Le; Paziaud, Olivier; Piot, Olivier; Saïd, M. Aït; Copie, Xavier; Lavergne, Thomas; Guize, L

doi:10.1016/s0002-8703(03)00524-6

Cited by 238 publications

(80 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cost analysis revealed that rate control is a less costly strategy, mainly due to the absence of cardioversion associated hospitalization costs typical of the rhythm control group. Economic analyses based on AFFIRM, COCAF, and RACE trials revealed, that hospitalizations represent a major cost driver in the treatment of AF patients [13,14,17]. Over the 3.5 years of the AFFIRM study follow-up, the incremental cost of rhythm control compared with rate control exceeded $5000 per patient and rhythm control strategy was less cost effective given a wide range of cost assumptions.…”

Section: Discussionmentioning

confidence: 99%

The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation

Pietrasik

Kosior

Niewada

et al. 2007

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation

Pietrasik

Kosior

Niewada

et al. 2007

International Journal of Cardiology

View full text Add to dashboard Cite

“…The increase can only partly be explained by the aging population [3,4,5,6]. A substantial rise in hospitalisations due to AF has been reported, leading to an increasing economical burden on society [7,8,9,10]. …”

Section: Introductionmentioning

confidence: 99%

Atrial Fibrillation and Antithrombotic Therapy in a 75-Year-Old Population

Tveit¹,

Abdelnoor²,

Enger³

et al. 2007

Cardiology

View full text Add to dashboard Cite

Aims: To find the true prevalence of diagnosed and undiagnosed atrial fibrillation (AF) in a population aged 75 years in 2 municipalities in Norway, and to study the use of antithrombotic therapy in this group. Methods: All 1,117 citizens in Asker and Baerum municipalities in eastern Norway born in 1930 were invited to participate in a prevalence study of AF. Nine hundred and sixteen subjects (82%) were examined by electrocardiogram, and blood pressure and pulse rate were measured. Comorbidity and current medication were recorded. Results: AF was present in 92 subjects (10%; 95% CI 8.2–12.1%), including 33 with ECG-documented, paroxysmal AF. In addition, 8 subjects had a history of a single, transient episode of AF. AF was previously undiagnosed in 10 out of 916 (1.1%). In 77 of 82 patients with previously diagnosed AF (93.9%), antithrombotic therapy was compliant with international guidelines. Conclusion: Ten percent (95% CI 8.2–12.2%) in this 75-year-old population had AF. Compliance with international guidelines regarding antithrombotic therapy was high. Previously undiagnosed AF was found in only 10 out of 916 (1.1%).

show abstract

“…Over the last two decades, hospitalizations for PAF in the United States have increased by a factor of two to three [16], and it is estimated that 5.6 million Americans will suffer from PAF by 2050 [17], resulting in a substantial public health burden and extreme costs [18],…”

Section: Discussionmentioning

confidence: 99%